Which risks could break the thesis, and what would warn of them?
Serva Energy's Actinium-225 production relies on Radium-226 seed material obtained via the U.S. Department of Energy Isotope Program for its initial batches; since this isotope is classified as waste and heavily controlled, that input supply is a concentration risk rather than an open-market purchase.
National laboratories and other suppliers offer only trivial quantities of Actinium, a scarcity Serva said severely restricts work on this cancer treatment approach.
2Product Overview
What does the product do for its buyer, and how is it delivered?
Serva Energy provides an Actinium-225 supply route rather than a therapy, having developed a production method that raises output of the cancer-killing isotope in demand among oncology researchers and pharmaceutical companies developing Targeted Alpha Therapies. Radiopharmaceutical developers pair the isotope with targeting antibodies, and bound to those antibodies it delivers a localized alpha-radiation dose to cancer cells with little harm to nearby healthy tissue.
Serva Energy first used a conventional nuclear reactor for production, allowing dozens of existing research reactors to collaborate. This approach required no large capital investment and avoided construction delays.
